Prof. Tadeusz Robak

Department of Hematology, Medical University of Lodz

Copernicus Memorial Hospital, Poland

Email: [email protected]

Qualifications

1993 Professor, Medical University of Lodz, Poland

1979 Ph.D., Medical University of Lodz, Poland

1973 M.D., Medical University of Lodz, Poland

Publications (Selected)

1. Shadman, M., Munir, T., Robak, T., Brown, J. R., Kahl, B. S., Ghia, P., ... & Jurczak, W. (2025). Zanubrutinib versus bendamustine and rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. Journal of Clinical Oncology, 43(7), 780-787.
2. Robak, T., Robak, M., Majchrzak, A., Krawczyńska, A., & Braun, M. (2025). Atypical Hairy Cell Leukemia—The Current Status and Future Directions. European Journal of Haematology.
3. Brown, J. R., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., ... & Shadman, M. (2024). Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood, 144(26), 2706-2717.
4. Shadman, M., Munir, T., Robak, T., Brown, J. R., Kahl, B. S., Ghia, P., ... & Jurczak, W. (2024). Sustained Superiority of Zanubrutinib vs Bendamustine+ Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study. Blood, 144, 3249.
5. Niemann, C. U., Munir, T., Owen, C., Follows, G., Rivas, J. A. H., Benjamini, O., ... & Kater, A. P. (2024). First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis. Blood, 144, 1871.
6. Paziewska, M., Szelest, M., Kiełbus, M., Masternak, M., Zaleska, J., Wawrzyniak, E., ... & Giannopoulos, K. (2024). Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia. Oncology letters, 28(5), 552.
7. Wang, M., Robak, T., Maddocks, K. J., Phillips, T., Smith, S. D., Gallinson, D., ... & Jurczak, W. (2024). Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Advances, 8(17), 4539-4548.
8. Woyach, J. A., Jones, D., Jurczak, W., Robak, T., Illés, Á., Kater, A. P., ... & Munugalavadla, V. (2024). Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood, 144(10), 1061-1068.
9. Burger, J., Barr, P., Robak, T., Owen, C., Tedeschi, A., Sarma, A., ... & Kipps, T. J. (2024). Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Clinical Lymphoma Myeloma and Leukemia, 24, S179.
10. Robak, T., Puła, A., Braun, M., & Robak, E. (2024). Extramedullary and extranodal manifestations in chronic lymphocytic leukemia–an update. Annals of Hematology, 103(9), 3369-3383.
11. Kubicki, T., Dytfeld, D., Barnidge, D., Sakrikar, D., Przybyłowicz-Chalecka, A., Jamroziak, K., ... & Derman, B. A. (2024). Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood, 144(9), 955-963.
12. Grever, M., Andritsos, L., Anghelina, M., Arons, E., Banerji, V., Barrientos, J., ... & Zinzani, P. L. (2024). Hairy cell leukemia variant and WHO classification correspondence Re: WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia, 38(7), 1642-1644.
13. Ma, S., Munir, T., Lasica, M., Shadman, M., Tedeschi, A., Ferrant, E., ... & Robak, T. (2024, June). Combination of zanubrutinib+ venetoclax for treatment-naive CLL/SLL with del (17p) and/or TP53: preliminary results from SEQUOIA arm D. In EHA Congress (pp. 13-16).
14. Brown, J. R., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., ... & Tedeschi, A. (2024). Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database. Haematologica, 109(7), 2277.
15. Puła, B., Iskierka-Jażdżewska, E., Jamroziak, K., Giannopoulos, K., Wróbel, T., Robak, T., & Hus, I. (2024). Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment. Acta Haematologica Polonica, 55(3), 130-136.
16. Niemann, C. U., Munir, T., Moreno, C., Owen, C., Follows, G. A., Benjamini, O., ... & Kater, A. P. (2023). Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(12), 1423-1433.
17. Moreno, C., Munir, T., Owen, C., Follows, G., Rivas, J. A. H., Benjamini, O., ... & Kater, A. P. (2023). First-line fixed-duration ibrutinib plus venetoclax (Ibr+ Ven) versus chlorambucil plus obinutuzumab (Clb+ O): 55-month follow-up from the glow study. Blood, 142, 634.
18. Iskierka-Jazdzewska, E., Kim, W. S., Cho, S. G., Kim, T. M., Jarque, I., Robak, T., ... & Walewski, J. (2023). Health-related quality of life and symptoms in patients with relapsed or refractory diffuse large b-cell lymphoma treated with odronextamab monotherapy in the phase 2 ELM-2 Study. Blood, 142, 4504.
19. Sekeres, M. A., Montesinos, P., Novak, J., Wang, J., Jeyakumar, D., Tomlinson, B., ... & Cortes, J. E. (2023). Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia, 37(10), 2017-2026.
20. Robak, T., Krawczyńska, A., Cebula-Obrzut, B., Urbaniak, M., Iskierka-Jażdżewska, E., & Robak, P. (2023). Atypical chronic lymphocytic leukemia—the current status. Cancers, 15(18), 4427.

Profile Details

WoS ResearcherID: AAW-7365-2021

https://orcid.org/0000-0002-3411-6357

https://pl.linkedin.com/in/tadeusz-robak-378542211

https://scholar.google.com.hk/citations?user=Ft6IndAAAAAJ&hl=en

https://www.researchgate.net/profile/Tadeusz-Robak